Sep 19, 2017

Oncolytics Biotech® to Present at the Phacilitate Immuno-Oncology Frontiers Conference

Sep 18, 2017

Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer

Sep 14, 2017

Oncolytics Biotech® Announces First Patient Treated in MUK eleven Study

Sep 11, 2017

Oncolytics Biotech® Announces the Presentation of REOLYSIN® Clinical Data at ESMO 2017 Congress

Aug 3, 2017

Oncolytics Biotech® Inc. Announces 2017 Second Quarter Results

Aug 1, 2017

Oncolytics Biotech® Inc. to Present at the Canaccord Genuity 37th Annual Growth Conference

Jul 26, 2017

Oncolytics Biotech® to Present REOLYSIN® Safety Data in combination with chemotherapy at ESMO 2017 Congress

Jun 29, 2017

Oncolytics® Biotech Inc. Appoints Andrew de Guttadauro, President of Oncolytics Biotech (U.S.) Inc.

Jun 27, 2017

Oncolytics Biotech® Inc. Opens U.S. Based Office in San Diego

Jun 1, 2017

Oncolytics Biotech® Announces Closing of Public Offering of Units